Immatics (IMTX)
(Delayed Data from NSDQ)
$6.18 USD
-0.14 (-2.22%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $6.30 +0.12 (1.94%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
IMTX 6.18 -0.14(-2.22%)
Will IMTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for IMTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IMTX
Dynavax Technologies (DVAX) Q2 Earnings and Revenues Beat Estimates
Does Immatics (IMTX) Have the Potential to Rally 174.54% as Wall Street Analysts Expect?
IMTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
ImmunityBio (IBRX) Reports Q1 Loss, Tops Revenue Estimates
Cardiff Oncology (CRDF) Reports Q1 Loss, Lags Revenue Estimates
Day One Biopharmaceuticals, Inc. (DAWN) Reports Q1 Loss, Tops Revenue Estimates
Other News for IMTX
IMTX Makes Bullish Cross Above Critical Moving Average
Iovance Biotherapeutics: ASCO Update, Competitor Data And The Road Ahead
Immatics N.V. Shareholders Approve Key Resolutions at June 2025 AGM
Tracking Baker Brothers Portfolio - Q1 2025 Update
Immatics: Taking Off On A PRAME Rocketship